Table 1.
Antiproliferative activity of 5-Aza-CdR, FK228 and oxaliplatin in SNU-638 and SNU-719 human gastric cancer cells
| SNU-638 | 24 h | 48 h | 72 h | |
|---|---|---|---|---|
| 5-Aza-CdR | IC50 | 4.52 ± 0.27 | 1.01 ± 0.13 | 0.89 ± 0.21 |
| R | 36.1 ± 9.9 | 33.9 ± 4.2 | 30.3 ± 5.8 | |
| FK228 | IC50 | 16.4 ± 8.9 | 3.72 ± 0.03 | 2.68 ± 0.13 |
| R | 31.7 ± 1.9 | 4.11 ± 4.00 | 2.56 ± 2.24 | |
| Oxaliplatin | IC50 | 35.4 ± 7.3 | 6.63 ± 1.24 | 0.68 ± 0.15 |
| R | 39.6 ± 6.6 | 15.2 ± 18.2 | 13.0 ± 6.15 | |
| SNU-719 | 24 h | 48 h | 72 h | |
|---|---|---|---|---|
| 5-Aza-CdR | IC50 | ND | 7.72 ± 0.01 | 5.76 ± 3.44 |
| R | 52.7 ± 1.9 | 48.1 ± 3.1 | 47.8 ± 1.9 | |
| FK228 | IC50 | ND | 5.61 ± 0.08 | 3.06 ± 0.004 |
| R | 55.3 ± 4.2 | 25.5 ± 2.05 | 2.67 ± 2.03 | |
| Oxaliplatin | IC50 | ND | 328 ± 3.9 | 1.24 ± 0.07 |
| R | 72.7 ± 5.07 | 47.8 ± 2.0 | 36.6 ± 0.76 | |
Cell viability was determined using the MTS assay. IC50, the drug concentration that produces a 50% of the drug’s maximum effect following 48 or 72 h of continuous exposure; expressed in nM for FK228 and μM for 5-Aza-CdR and oxaliplatin. R, the residual unaffected fraction (resistance fraction); IC50 and R values were determined from dose-response curves analyzed using Eq. 1 and Eq. 2 (see Materials and Methods). Data are presented as the mean ± SD from at least three independent experiments. ND, not determined.